Know Cancer

forgot password

A Randomized, Multicenter, Phase III Open-label Study of the Efficacy and Safety of Trastuzumab Emtansine vs. Capecitabine + Lapatinib in Patients With HER2-positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-based Therapy

Phase 3
18 Years
Open (Enrolling)
Breast Cancer

Thank you

Trial Information

A Randomized, Multicenter, Phase III Open-label Study of the Efficacy and Safety of Trastuzumab Emtansine vs. Capecitabine + Lapatinib in Patients With HER2-positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-based Therapy

Inclusion Criteria:

- (Human epidermal growth factor receptor 2 (HER2) status must be prospectively,
centrally tested and be HER2-positive based on central laboratory assay results.

- Histologically or cytologically confirmed invasive breast cancer.

- Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced, or
metastatic setting must include both a taxane, alone or in combination with another
agent, and trastuzumab, alone or in combination with another agent.

- Documented progression of incurable, unresectable, locally advanced or metastatic
breast cancer, defined by the investigator.

- Measurable and/or nonmeasurable disease; patients with central nervous system
(CNS)-only disease are excluded.

- Cardiac ejection fraction ≥ 50% by either echocardiogram (ECHO) or multi-gated
acquisition (MUGA) scan.

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

- For women of childbearing potential and men with partners of childbearing potential,
agreement to use a highly effective, non-hormonal form of contraception;
contraception use should continue for the duration of the study treatment and for at
least 6 months after the last dose of study treatment.

Exclusion Criteria:

- History of treatment with trastuzumab emtansine (T-DM1).

- Prior treatment with lapatinib or capecitabine.

- Peripheral neuropathy of Grade ≥ 3 per National Cancer Institute Common Terminology
Criteria for Adverse Events (NCI-CTCAE), Version 3.0.

- History of other malignancy within the last 5 years, except for appropriately treated
carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage 1 uterine cancer,
synchronous or previously diagnosed HER2-positive breast cancer, or cancers with a
similar curative outcome as those mentioned above.

- History of receiving any anti-cancer drug/biologic or investigational treatment
within 21 days prior to randomization except hormone therapy, which could be given up
to 7 days prior to randomization; recovery of treatment-related toxicity consistent
with other eligibility criteria.

- History of radiation therapy within 14 days of randomization.

- Brain metastases that are untreated, symptomatic, or require therapy to control
symptoms, as well as any history of radiation, surgery, or other therapy, including
steroids, to control symptoms from brain metastases within 2 months (60 days) of

- History of symptomatic congestive heart failure (CHF) or serious cardiac arrhythmia
requiring treatment.

- History of myocardial infarction or unstable angina within 6 months of randomization.

- Current dyspnea at rest due to complications of advanced malignancy or current
requirement for continuous oxygen therapy.

- Current severe, uncontrolled systemic disease (eg, clinically significant
cardiovascular, pulmonary, or metabolic disease).

- Pregnancy or lactation.

- Current known active infection with human immunodeficiency virus (HIV), hepatitis B
virus, or hepatitis C virus.

- Presence of conditions that could affect gastrointestinal absorption: Malabsorption
syndrome, resection of the small bowel or stomach, and ulcerative colitis.

- History of intolerance (such as Grade 3-4 infusion reaction) to trastuzumab.

- Known hypersensitivity to 5-fluorouracil or known dihydropyrimidine dehydrogenase

- Current treatment with sorivudine or its chemically related analogs, such as

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression-free Survival (PFS) Assessed by an Independent Review Committee

Outcome Description:

PFS was defined as the time from randomization to progressive disease (PD) or death from any cause, whichever occurred earlier. All measurable lesions up to a maximum of 5 per organ and 10 in total, representative of all involved organs, should be identified as target lesions (TL) and recorded and measured at baseline. TLs should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements either by imaging or clinically. A sum of the longest diameter for all TLs will be calculated and reported as the baseline sum longest diameter (SLD). All other lesions (or sites of disease) should be identified as non-TLs and recorded at baseline. PD for TLs was defined as ≥ 20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs.

Outcome Time Frame:

From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)

Safety Issue:


Principal Investigator

Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:



United States: Food and Drug Administration

Study ID:




Start Date:

February 2009

Completion Date:

April 2014

Related Keywords:

  • Breast Cancer
  • Breast Neoplasms



Hinsdale, Illinois  60521
New Britain, Connecticut  06052
Bettendorf, Iowa  52722
Alexandria, Minnesota  56308
Albany, Georgia  31701
Great Falls, Montana  59405
Phoenix, Arizona  85012
Fountain Valley, California  92708
Miami, Florida  33176
Columbia, Missouri  65203
Albany, New York  12208
Cleveland, Ohio  44195
Philadelphia, Pennsylvania  19104
Nashville, Tennessee  37203-1632
Austin, Texas  78705
Seattle, Washington  98195
Flint, Michigan  48532
Louisville, Kentucky  40207
McLean, Virginia  22101
Kansas City, Kansas  66160
Scarborough, Maine  04074
Omaha, Nebraska  68114
Hackensack, New Jersey  07601
Albuquerque, New Mexico  87131-5636
Metairie, Louisiana  70006
Denver, Colorado  
Baltimore, Maryland  21287
Boston, Massachusetts  
Charlotte, North Carolina  
Eugene, Oregon  
Milwaukee, Wisconsin  
Charleston, South Carolina  
Providence, Rhode Island  02908
Washington, District of Columbia  
Las Vegas, Nevada  89109
Coeur D'alene, Idaho  83814